The availability of our team to support you has not changed as a result of COVID-19. If there is a way we can assist you, we are here to help - Contact us

Horizon Sign Commercial Screening Agreement with SuperGen Inc.

15 Jul 2009

Horizon Discovery (Horizon) today announced it has signed a commercial agreement with US Pharmaceutical company; SuperGen, Inc., relating to its X-MAN™ technology.

Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to rationalize key steps of the ‘targeted’ drug development process, and thus accelerate and economize the burgeoning field of ‘personalised’ medicine.

The agreement covers the screening of a number of lead compounds on a wide panel of human isogenic cell-lines comprising target genotypes of interest to SuperGen. The approach may enable SuperGen to gather information relating to the selectivity and mode-of-action of their compounds using model in-vitro systems.

“Dr Darrin M Disley, Commercial Director and Chairman of Horizon says “working with SuperGen is an exciting development for Horizon. In this expandable agreement, we hope to further prove the potential of our human X-MAN models in a screening environment; thus facilitating a long and productive relationship with SuperGen.”

SuperGen will pay Horizon undisclosed fees during the term of the agreement.

Work between the parties will begin in July 2009.